drugset / Trial / NCT05633446
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
RandomizedParallel-groupDouble-blindPrevention
Summary
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PepGNP-COVID19 | Vaccine | 47.8 ug | — |
| Subject | PepGNP-COVID19 | Vaccine | 7.5 unknown | — |